| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
CV-1808 targets adenosine receptors, specifically the A2A and A3 subtypes. It exhibits a Ki of 76 nM for the A2A receptor and a Ki of 1450 nM for the A3 receptor. This indicates a significant selectivity for the A2A subtype over the A3 subtype. By activating these receptors, CV-1808 modulates various downstream signaling pathways, including the cAMP pathway.
|
|---|---|
| ln Vitro |
CV1808 has inhibitory effects against IgE-induced activation at 100 μM [1]. CV1808 has an EC50 value of 2 μM in the presence of forskolin (1 μM in PC12 cells; 10 μM in Jurkat cells) [2].
In vitro, CV-1808 has inhibitory effects against IgE-induced activation at 100 µM. It also exhibits an EC50 value of 2 µM in the presence of forskolin (1 µM in PC12 cells; 10 µM in Jurkat cells). These findings suggest that CV-1808 can modulate immune cell function and intracellular signaling pathways, consistent with its role as an adenosine receptor agonist. |
| ln Vivo |
Sprague-Dawley rats' single afferent arterioles were examined and perfused with a solution containing CV1808 (CV-1808). Afferent arterioles dilate when CV1808 (0.002-2 μM) is infused [3].
In vivo, CV-1808 has been shown to induce vasodilation in rat models. In studies on single afferent arterioles from Sprague-Dawley rats, infusion of CV-1808 (0.002-2 µM) caused afferent arteriolar dilation. At concentrations of 0.002, 0.02, 0.2, and 2 µM, the afferent arteriolar diameter increased from 17.0±0.3 to 17.2±0.4, 17.8±0.4, 18.5±0.5, and 19.9±0.7 µM, respectively. |
| Enzyme Assay |
In cell-free receptor binding assays, CV-1808's affinity for adenosine receptors is determined using radioligand binding techniques. Membrane preparations from cells expressing the A2A or A3 receptor are incubated with a radiolabeled antagonist (e.g., [3H]ZM241385 for A2A or [125I]AB-MECA for A3) and varying concentrations of CV-1808. The displacement of the radioligand is measured, and the inhibition constant (Ki) is calculated from the competition curve.
|
| Cell Assay |
In vitro cell-based experiments with CV-1808 typically involve cultured cells expressing adenosine receptors, such as PC12 cells (which express A2A receptors) or Jurkat T cells. Cells are treated with the compound in the presence or absence of forskolin, and the accumulation of cyclic AMP (cAMP) is measured as a readout of receptor activation. Alternatively, the compound's effect on IgE-induced activation in mast cells or basophils can be assessed.
|
| Animal Protocol |
Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rat, body weight 370-410 g[3]
Doses: 0.002, 0.02, 0.2 and 2 μM Route of Administration: Observe the single afferent arteriole of SD (SD (Sprague-Dawley)) rats and perfuse containing CV- Solution results of 1808: At concentrations of 0.002, 0.02, 0.2 and 2 μM, afferent arteriolar diameter increased from 17.0±0.3 to 17.2±0.4, 17.8±0.4, 18.5±0.5 and 19.9±0.7 μM, 17.2±2.4% . In vivo animal experiments with CV-1808 have been conducted in rat models to study its vasodilatory effects. In one protocol, single afferent arterioles from male Sprague-Dawley rats are isolated and perfused with a solution containing the compound at various concentrations (0.002-2 µM). The change in arteriolar diameter is measured to assess the vasodilatory response. |
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data is publicly available for CV-1808. As a research compound, its absorption, distribution, metabolism, and excretion (ADME) properties have not been extensively characterized. It is a small molecule (molecular weight 358.36) that is typically administered in vitro or via perfusion in ex vivo studies. Its bioavailability and half-life in vivo have not been well established.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is publicly available for CV-1808. In cell-based assays, it is used at concentrations up to 100 µM, indicating a relatively low acute toxicity in vitro. The compound is for research use only and is not intended for human therapeutic applications. No systemic toxicity studies have been reported in the available literature.
|
| References |
|
| Additional Infomation |
2-Phenylanadenosine is a purine nucleoside.
CV-1808 is a non-selective A2 adenosine receptor agonist with a molecular formula of C16H18N6O4 and a molecular weight of 358.36. It is also known as 2-Phenylaminoadenosine. The compound is a valuable research tool for studying adenosine receptor pharmacology, particularly the roles of A2A and A3 receptors in vasodilation, inflammation, and immune modulation. It is available for research purposes only and is not approved for clinical use. |
| Molecular Formula |
C16H18N6O4
|
|---|---|
| Molecular Weight |
358.36
|
| Exact Mass |
358.139
|
| CAS # |
53296-10-9
|
| PubChem CID |
6917803
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.78g/cm3
|
| Boiling Point |
766ºC at 760mmHg
|
| Melting Point |
210-212ºC
|
| Flash Point |
417.1ºC
|
| Index of Refraction |
1.829
|
| LogP |
0.417
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
26
|
| Complexity |
482
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=CC=C(C=C1)NC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N
|
| InChi Key |
SCNILGOVBBRMBK-SDBHATRESA-N
|
| InChi Code |
InChI=1S/C16H18N6O4/c17-13-10-14(21-16(20-13)19-8-4-2-1-3-5-8)22(7-18-10)15-12(25)11(24)9(6-23)26-15/h1-5,7,9,11-12,15,23-25H,6H2,(H3,17,19,20,21)/t9-,11-,12-,15-/m1/s1
|
| Chemical Name |
(2R,3R,4S,5R)-2-(6-amino-2-anilinopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
|
| Synonyms |
CV1808; CV 1808; CV-1808
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7905 mL | 13.9525 mL | 27.9049 mL | |
| 5 mM | 0.5581 mL | 2.7905 mL | 5.5810 mL | |
| 10 mM | 0.2790 mL | 1.3952 mL | 2.7905 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
